Grenada vs Vietnam: Statin use vs. average non-HDL cholesterol levels
Grenada
3.5
in 2018
Vietnam
3.5
in 2018
Grenada rank
52nd
Vietnam rank
52nd
Statin use vs. average non-HDL cholesterol levels over time
- Grenada
- Vietnam
How they compare
Grenada currently reports 3.5 against 3.5 in Vietnam, a difference of 0.
The two have swapped places 3 times across 39 shared years of data; in 1980 it was Grenada ahead.
Grenada ranks 52nd and Vietnam ranks 52nd of 191 countries.
Grenada has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Grenada | Vietnam | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.2 | 2.81 | 0.39 | Grenada |
| 1990s | 3.25 | 2.93 | 0.32 | Grenada |
| 2000s | 3.33 | 3.12 | 0.21 | Grenada |
| 2010s | 3.46 | 3.39 | 0.0667 | Grenada |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Grenada or Vietnam?
- Grenada, at 3.5 against 3.5 in Vietnam as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Grenada and Vietnam?
- 0, with Grenada ahead.
- How many years of comparable data are there for Grenada and Vietnam?
- 39 years are reported by both, from 1980 to 2018.
- How do Grenada and Vietnam rank globally for statin use vs. average non-hdl cholesterol levels?
- Grenada ranks 52nd and Vietnam ranks 52nd of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.